|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:oxaliplatin
|
|
gptkbp:affiliatedWith
|
platinum-based antineoplastic agents
|
|
gptkbp:approvedBy
|
2002
|
|
gptkbp:ATCCode
|
L01XA03
|
|
gptkbp:CASNumber
|
61825-94-3
|
|
gptkbp:chemicalFormula
|
C8H14N2O4Pt
|
|
gptkbp:contraindication
|
hypersensitivity to platinum compounds
|
|
gptkbp:eliminationHalfLife
|
9-25 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:FDAApproved
|
approved
|
|
gptkbp:heldBy
|
gptkb:antineoplastic_agent
|
|
gptkbp:indication
|
adjuvant treatment of stage III colon cancer
treatment of advanced colorectal cancer
|
|
gptkbp:KEGGID
|
gptkb:D01841
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Sanofi
|
|
gptkbp:mechanismOfAction
|
platinum-based DNA crosslinker
|
|
gptkbp:MedlinePlusID
|
a607045
|
|
gptkbp:metabolism
|
non-enzymatic biotransformation
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1351
DB00526
6857598
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:peripheral_neuropathy
nausea
vomiting
diarrhea
myelosuppression
|
|
gptkbp:UNII
|
04ZR38536J
|
|
gptkbp:usedFor
|
colorectal cancer
|
|
gptkbp:bfsParent
|
gptkb:oxaliplatin
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eloxatin
|